Cargando…

Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges

SIMPLE SUMMARY: Over the past decade, cell-based immunotherapy has become a powerful strategy in solid cancer therapy. Tumor-infiltrating lymphocytes (TILs) are a group of intratumor lymphocytes. With the development of new technologies, the isolation and generation of TILs from tumor tissues have i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yueshui, Deng, Jian, Rao, Shuangfeng, Guo, Sipeng, Shen, Jing, Du, Fukuan, Wu, Xu, Chen, Yu, Li, Mingxing, Chen, Meijuan, Li, Xiaobing, Li, Wanping, Gu, Li, Sun, Yuhong, Zhang, Zhuo, Wen, Qinglian, Xiao, Zhangang, Li, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455018/
https://www.ncbi.nlm.nih.gov/pubmed/36077696
http://dx.doi.org/10.3390/cancers14174160
_version_ 1784785489643962368
author Zhao, Yueshui
Deng, Jian
Rao, Shuangfeng
Guo, Sipeng
Shen, Jing
Du, Fukuan
Wu, Xu
Chen, Yu
Li, Mingxing
Chen, Meijuan
Li, Xiaobing
Li, Wanping
Gu, Li
Sun, Yuhong
Zhang, Zhuo
Wen, Qinglian
Xiao, Zhangang
Li, Jing
author_facet Zhao, Yueshui
Deng, Jian
Rao, Shuangfeng
Guo, Sipeng
Shen, Jing
Du, Fukuan
Wu, Xu
Chen, Yu
Li, Mingxing
Chen, Meijuan
Li, Xiaobing
Li, Wanping
Gu, Li
Sun, Yuhong
Zhang, Zhuo
Wen, Qinglian
Xiao, Zhangang
Li, Jing
author_sort Zhao, Yueshui
collection PubMed
description SIMPLE SUMMARY: Over the past decade, cell-based immunotherapy has become a powerful strategy in solid cancer therapy. Tumor-infiltrating lymphocytes (TILs) are a group of intratumor lymphocytes. With the development of new technologies, the isolation and generation of TILs from tumor tissues have improved. Clinical use of TILs for solid tumor treatment showed good efficacy. In this review, we summarize the current strategies and challenges of TIL generation. We highlight the clinical trials where TIL therapy is used independently and in combination with other therapies for solid tumor treatment. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed. ABSTRACT: Over the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of cell-based immunotherapy using the patient’s own immune cells from the microenvironment of the solid tumor to kill tumor cells. In this review, we provide a comprehensive summary of the current strategies and challenges in TIL isolation and generation. Moreover, the current clinical experience of TIL therapy is summarized and discussed, with an emphasis on lymphodepletion regimen, the use of interleukin-2, and related toxicity. Furthermore, we highlight the clinical trials where TIL therapy is used independently and in combination with other types of therapy for solid cancers. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed.
format Online
Article
Text
id pubmed-9455018
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94550182022-09-09 Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges Zhao, Yueshui Deng, Jian Rao, Shuangfeng Guo, Sipeng Shen, Jing Du, Fukuan Wu, Xu Chen, Yu Li, Mingxing Chen, Meijuan Li, Xiaobing Li, Wanping Gu, Li Sun, Yuhong Zhang, Zhuo Wen, Qinglian Xiao, Zhangang Li, Jing Cancers (Basel) Review SIMPLE SUMMARY: Over the past decade, cell-based immunotherapy has become a powerful strategy in solid cancer therapy. Tumor-infiltrating lymphocytes (TILs) are a group of intratumor lymphocytes. With the development of new technologies, the isolation and generation of TILs from tumor tissues have improved. Clinical use of TILs for solid tumor treatment showed good efficacy. In this review, we summarize the current strategies and challenges of TIL generation. We highlight the clinical trials where TIL therapy is used independently and in combination with other therapies for solid tumor treatment. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed. ABSTRACT: Over the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of cell-based immunotherapy using the patient’s own immune cells from the microenvironment of the solid tumor to kill tumor cells. In this review, we provide a comprehensive summary of the current strategies and challenges in TIL isolation and generation. Moreover, the current clinical experience of TIL therapy is summarized and discussed, with an emphasis on lymphodepletion regimen, the use of interleukin-2, and related toxicity. Furthermore, we highlight the clinical trials where TIL therapy is used independently and in combination with other types of therapy for solid cancers. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed. MDPI 2022-08-27 /pmc/articles/PMC9455018/ /pubmed/36077696 http://dx.doi.org/10.3390/cancers14174160 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zhao, Yueshui
Deng, Jian
Rao, Shuangfeng
Guo, Sipeng
Shen, Jing
Du, Fukuan
Wu, Xu
Chen, Yu
Li, Mingxing
Chen, Meijuan
Li, Xiaobing
Li, Wanping
Gu, Li
Sun, Yuhong
Zhang, Zhuo
Wen, Qinglian
Xiao, Zhangang
Li, Jing
Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
title Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
title_full Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
title_fullStr Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
title_full_unstemmed Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
title_short Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
title_sort tumor infiltrating lymphocyte (til) therapy for solid tumor treatment: progressions and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455018/
https://www.ncbi.nlm.nih.gov/pubmed/36077696
http://dx.doi.org/10.3390/cancers14174160
work_keys_str_mv AT zhaoyueshui tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT dengjian tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT raoshuangfeng tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT guosipeng tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT shenjing tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT dufukuan tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT wuxu tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT chenyu tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT limingxing tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT chenmeijuan tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT lixiaobing tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT liwanping tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT guli tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT sunyuhong tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT zhangzhuo tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT wenqinglian tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT xiaozhangang tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges
AT lijing tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges